Showing results (81-90 of 90) with videos related to
Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Journal of Applied Clinical Medical Physics|August 3, 2022
Abdominopelvic MR to CT registration using a synthetic CT intermediateJin Uk Heo, Feifei Zhou, Robert Jones, et al.Cancer Research|November 29, 2013
Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imagingMichael D Allen, Phuong Luong, Chantelle Hudson, et al.The Lancet. Oncology|June 24, 2014
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trialGary Middleton, Paul Silcocks, Trevor Cox, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2026
Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority TrialTimothy Iveson, Mark P Saunders, Caroline Kelly, et al.JAMA Surgery|June 12, 2024
Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy: Post Hoc Analysis of the SCOT Randomized Clinical TrialMikail Gögenur, Andreas Weinberger Rosen, Timothy Iveson, et al.The Lancet. Oncology|April 4, 2018
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trialTimothy J Iveson, Rachel S Kerr, Mark P Saunders, et al.British Journal of Cancer|November 14, 2018
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancerJosé Robles-Zurita, Kathleen A Boyd, Andrew H Briggs, et al.Health Technology Assessment (Winchester, England)|December 20, 2019
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCTTimothy Iveson, Kathleen A Boyd, Rachel S Kerr, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2023
Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the ProstateSoumyajit Roy, Tahmineh Romero, Jeff M Michalski, et al.Nature Communications|September 6, 2023
A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancerCorina E Antal, Tae Gyu Oh, Stefan Aigner, et al.Pageof 9